Vascular Ventures, LLC v. American Vascular Access, LLC

CourtDistrict Court, S.D. Alabama
DecidedOctober 16, 2017
Docket1:16-cv-00481
StatusUnknown

This text of Vascular Ventures, LLC v. American Vascular Access, LLC (Vascular Ventures, LLC v. American Vascular Access, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. Alabama primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vascular Ventures, LLC v. American Vascular Access, LLC, (S.D. Ala. 2017).

Opinion

FOR THE SOUTHERN DISTRICT OF ALABAMA SOUTHERN DIVISION

VASCULAR VENTURES, LLC, ) Plaintiff, ) ) v. ) CIVIL ACTION: 16-00481-KD-B ) AMERICAN VASCULAR ACCESS, LLC ) and JANET R. DEES, ) Defendants. )

ORDER

This matter is before the Court on Defendants’ motion for summary judgment (American Vascular Access, LLC (Access) and Janet R. Dees (Dees)) (Doc. 91), Plaintiff Vascular Ventures, LLC (Plaintiff)’s Response (Doc. 93) and Defendants’ Reply (Doc. 99). I. Background This action stems from Plaintiff’s August 9, 2016 complaint, 02-CV-2016-901640, filed in the Circuit Court of Mobile County, Alabama against Dees, Access, “any subsidiary” of Access “formed after December 30, 2009[,]” and “nominal” defendants. (Doc. 1-2). On September 12, 2016, Access removed the case on the basis of federal diversity subject matter jurisdiction. (Doc. 1). On December 7, 2016, the Court issued an R&R on the parties’ respective motions to dismiss, transfer and remand, through which the Court denied remand and transfer, dismissed all defendants except Access and Dees, and dismissed all claims except for breach of contract based on a December 30, 2009 letter (Count One), promissory fraud (Count Three) and civil conspiracy (Count Six). (Doc. 28). On December 28, 2016, the R&R was adopted. (Doc. 29); Vascular Ventures, LLC v. American Vascular Access, LLC, 2016 WL 7471642 (S.D. Ala. Dec. 7, 2016), R&R adopted (S.D. Ala. Dec. 28, 2016).1 On August 18, 2017, Access and Dees

1 For clarification: “[n]otwithstanding…[Access’] repeated representations….that it is a party to the Purchase Agreement, the agreement itself places the matter beyond dispute that…[it] is neither a signatory nor a party to that agreement[.]” Id. at n.6. The Court found as follows with regard to the relevance of the Purchase 1 II. Findings of Fact2 From 2008-2009, Access negotiated with Plaintiff and its members (physicians)3 to purchase a 40% interest in Plaintiff’s lab-based interventional nephrology practice in Mobile, Alabama (which ultimately became Mobile Vascular Labs, LLC). As an “additional incentive” to Access’ payment to Plaintiff for that 40% interest, Access promised to reserve a minimum of up to 10% of Access’ portion of future joint ventures and business opportunities for Plaintiff. In November 2009, the parties discussed what those future opportunities might entail. Also, Access’ President Janet Dees (Dees) explained to Plaintiff that she intended for the ventures to be entered into by separate new holding companies that would be created as co-owners in other dialysis access clinics. (Doc. 95-2 SEALED (Dep. Dees at 181-189). Specifically, separate holding companies, originating from Access, would be formed to hold equity positions in new ventures through which Access would perform development and management services for the holding companies and have an ownership interest in them.

Agreement, and whether the Side Letter was incorporated into the Purchase Agreement as an “ancillary agreement”:

It is without dispute in this case that the parties to the December 30, 2009, Purchase Agreement are nine individual doctors….(all non-parties to this case), M[obile] V[ascular] L[abs]… (a non-party to this case), and…[American Vascular Access Mobile Holdings, LLC] (a non-party to this case)…..Neither Plaintiff nor any Defendant in this case alleges that it is a party or an intended third-party beneficiary to that Purchase Agreement….On the other hand, with respect to Plaintiff’s claim that the Side Letter agreement is a stand alone contract between…[Access], Dees, and…[Plaintiff], the Court agrees that Plaintiff has at least stated a claim against these Defendants for breach of contract as to this agreement….The Side Letter document shows an executed, binding agreement signed by Dees, ostensibly on behalf of…[Access], to reserve a minimum of 10% of….[Access’] future business ventures for investment by…[Plaintiff] and its doctor members, in exchange for which Plaintiff/its doctor members would sell 40% off…[the Labs] to…[Access’] affiliate, [AVA]…

Id. at *14-15. The Court dismissed Plaintiff’s breach of contract claim based on the Purchase Agreement.

2 On summary judgment the Court must “resolve all issues of material fact in favor of the [non-movant], and then determine the legal question of whether the [movant] is entitled to judgment as a matter of law under that version of the facts.” McDowell v. Brown, 392 F.3d 1283, 1288 (11th Cir. 2004).

3 Plaintiff and its physician members will be referenced as Plaintiff in this Order. 2 (Doc. 91-1 (Dep. Dees at 493); Doc. 95-2 SEALED (Dep. Dees at 183-185). The parties discussed the first such “deal” for a business in the Atlanta, Georgia area. On November 24, 2009, Access’ Chief Operating Officer William G. Wright (Wright) e-mailed preliminary figures and estimates for the Atlanta “deal” (including investment cash flow, revenue assumptions, start up costs, etc.) to Plaintiff c/o Butera (Plaintiffs President), with a copy to Dees.*_ (Doc. 95-4 SEALED; Doc. 91-2 (Dep. Butera at 170-171, 173); Doc. 91-2 at 54; Doc. 95-3 SEALED (Dep. Wright at 154); Doc. 95-6 SEALED (Dep. Butera at 68)). On December 30, 2009, Access issued a letter to Plaintiff (the Side Letter) stating the parties’ intentions: /_ □ = AMERICAN VASCULAR CLALYS ACCESS CENTERS December 30, 2009 Dr. Phil Butera Dr. Craig KJinemann Vascular Wentures L.L.C. Mobile, Alabarna Doctors, , Pursuant to our letter of intent dated March 11, 2009 under section 8, tithed Additional Incentive. As additionel incentive to Vascular Wentures or its physician members, American Vascular (AVA) will reserve a minimum of up to 10% of AVA's portion of any future joint venture or business opportunity that may arise out of AWA"s general course of business, for Vascular Ventures doctors to invest. Vascular Ventures and its physicians will be offered the same terms and conditions es other investors and may elect or be offered additional ownership beyond but will always be offered at least 10% of positian. It is understood thar Vascular Ventures or its physician members involvement in these opportunities are optional and is on may arise” basis, Investment in these ventures will orost likely occur as a silent pariner in the vascular necess entity thet will be created. Investment im these deals will be solely optional on the part of Vascular Ventures. Should Vascular Ventures provide information or additional contacts, support opportunities te Amerioan Vascular that results In a business opportunity, then AWA will reserve editor ownership and investment opportunity to Wascular Wentures up to a mininvum of 25% of AVA"s portion. This opportunity is again at the option of Wascular Ventures.

Janct Dees

American Vascular Access

4 Per Plaintiff, Butera never saw until his deposition (and does not recall) the email from Access. Nor did he know that an offer regarding the Georgia venture “had been rendered” from Access, adding that Access was instructed to copy Harry Bishop. (Doc. 91-2 (Dep. Butera at 170-171, 173)).

Dees testified that per the Side Letter, Access planned for holding companies to be created for new vascular centers that Access might do business with and have ownership interest in, and Plaintiff would then have opportunities to buy at least a 10% interest in those holding companies. (Doc. 95-2 SEALED (Dep. Dees at 186-186); Doc. 95-3 SEALED (Dep. Wright at 240)). Per Access, the Side Letter created a contractual obligation on the part of Access to offer to Plaintiff at least a 10% interest in future investment opportunities. (Doc. 95-2 SEALED (Dep. Dees at 364-365)). See also (Doc. 95-3 SEALED (Dep.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

G.F. Kelly Trucking, Inc. v. U.S. Xpress Enterprises, Inc.
281 F. App'x 855 (Eleventh Circuit, 2008)
Roderic R. McDowell v. Pernell Brown
392 F.3d 1283 (Eleventh Circuit, 2004)
Klaxon Co. v. Stentor Electric Manufacturing Co.
313 U.S. 487 (Supreme Court, 1941)
Nihon Rufuto Co., LTD vs Nidek Medical Products, Inc.
437 F. App'x 782 (Eleventh Circuit, 2011)
J & M Associates, Inc. v. Frederick Romero
488 F. App'x 373 (Eleventh Circuit, 2012)
New Hampshire Insurance Company v. John A. Pankratz
516 F. App'x 803 (Eleventh Circuit, 2013)
Ex Parte Charles Bell Pontiac-Buick-Cadillac-GMC, Inc.
496 So. 2d 774 (Supreme Court of Alabama, 1986)
Oliner v. City of Englewood
593 P.2d 977 (Colorado Court of Appeals, 1979)
Robroy Land Co. v. Prather
622 P.2d 367 (Washington Supreme Court, 1980)
Hartnett v. Jones
629 P.2d 1357 (Wyoming Supreme Court, 1981)
Glass v. Southern Wrecker Sales
990 F. Supp. 1344 (M.D. Alabama, 1998)
Weber v. Texas Co.
83 F.2d 807 (Fifth Circuit, 1936)
Shaffer v. Regions Financial Corp.
29 So. 3d 872 (Supreme Court of Alabama, 2009)
Southland Bank v. a & a Drywall Supply Co.
21 So. 3d 1196 (Supreme Court of Alabama, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Vascular Ventures, LLC v. American Vascular Access, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vascular-ventures-llc-v-american-vascular-access-llc-alsd-2017.